{"url_path":"/sec/inm/8-k/2026-07-22/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1728328/0001213900-26-080414-index.html","accession_number":"0001213900-26-080414","cik":"0001728328","ticker":"INM","issuer_name":"InMed Pharmaceuticals Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1728328/0001213900-26-080414-index.html","primary_entity_key":"0001728328","primary_entity_name":"InMed Pharmaceuticals Inc."},"word_count":151,"has_tables":true,"body_markdown":"**Item 7.01 Regulation FD Disclosure.**\n\n \n\nOn July 22, 2026, Mentari Therapeutics, Inc. issued a press release\nannouncing the entry into the Amendment (as described in Item 8.01 of this Current Report on Form 8-K). The press release is furnished\nas Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, except that the information\ncontained on the website referenced in the press release is not incorporated herein by reference.\n\n \n\nThe information in this Item 7.01, including Exhibit 99.1,\nattached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended\n(the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated\nby reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”),or the Exchange Act,\nexcept as expressly set forth by specific reference in such filing."}